Skip to main
ANRO

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience is at an inflection point with the initiation of their Phase 2B study for ALTO-207 in TRD, with potential regulatory filings by 2028. However, there are commercial risks with market acceptance, financial risks with the need for additional capital, and potential regulatory risks with the use of accelerated strategies and reliance on third parties for clinical studies. Overall, the potential for personalized and effective treatments in the psychiatric market is promising, but caution should be taken with the associated risks.

Bears say

Alto Neuroscience is a clinical-stage biopharmaceutical company with a high level of financial risk due to the need for additional capital before becoming profitable and potential dilution for shareholders. The company also faces intellectual property risks and uncertainty with their unproven biomarker approach for precision medicines. Additionally, their drug candidates are in various stages of development, and clinical trials in depression have high failure rates, which could negatively impact the company's valuation.

ANRO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ANRO has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.